source
- Regeneron secures FDA approval for Pasatru, second U.S. treatment for rare bone disease FOPRegeneron received FDA approval for its antibody garetosmab, marketed as Pasatru, for treatment of fibrodysplasia ossificans progressiva (FOP) in adults. The approval makes Pasatru the second ther…
- Layoffs hit over 1,300 workers across seven biopharma M&A deals in 2026Workforce reductions this year have affected at least seven biopharma companies that recently completed mergers or acquisitions, eliminating a minimum of 1,359 jobs, according to BioSpace data. Th…